Convergence Pharmaceuticals Limited Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
Convergence Pharmaceuticals Limited announced that its novel sodium channel blocker, CNV1014802 ('802), has been granted orphan-drug designation by the US Food and Drug Administration for the treatment of trigeminal neuralgia (TN). Orphan-drug designation gives Convergence various incentives and advantages in the development of '802, including the potential availability of certain grants for clinical studies and assistance from the FDA with clinical protocol design. Furthermore orphan drug designation grants US market exclusivity, distinct from other types of exclusivity, for seven years if '802 is approved.
http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=114130142